KIT and gastrointestinal stromal tumor: The first study, ACOSOG Z9000, was a single-arm, multicenter trial in which 400 mg/day imatinib was administered for 1 year to 107 patients with resected KIT+ GIST who had a high risk of recurrence (DeMatteo et al., 2009).